# Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

> **NCT02311998** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
- CD22 Positive
- Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

## Interventions

- **DRUG:** Bosutinib
- **BIOLOGICAL:** Inotuzumab Ozogamicin

## Key facts

- **NCT ID:** NCT02311998
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-16
- **Primary completion:** 2022-03-23
- **Final completion:** 2022-03-23
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02311998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02311998, "Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02311998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*